Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6768219 | 0.98 | TAAR1 (0.50) | TAAR1KDM4EATMPKMALOX15 | |
| SCHEMBL11950523 | 0.86 | CA2 (0.48) | TAAR1PKMALOX15GAACA2 | |
| SCHEMBL19693044 | 0.85 | GABRA1 (0.52) | TAAR1KDM4EATMCSNK2A1ADRA1A | |
| SCHEMBL1848551 | 0.85 | TAAR1 (0.52) | TAAR1KDM4EATMCSNK2A1GAA | |
| SCHEMBL20286678 | 0.84 | CA2 (0.63) | TAAR1ATMPKMALOX15GAA | |
| SCHEMBL28215313 | 0.81 | HSD17B10 (0.47) | KDM4EATMPKMALOX15GAA | |
| SCHEMBL17072158 | 0.81 | CA2 (0.44) | TAAR1KDM4EATMPKMALOX15 | |
| SCHEMBL9886085 | 0.81 | GABRA1 (0.55) | TAAR1KDM4EATM | |
| SCHEMBL18264884 | 0.81 | PKM (0.46) | TAAR1PKMALOX15GAACA2 | |
| SCHEMBL23469221 | 0.80 | TAAR1 (0.51) | TAAR1KDM4EATMCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725467-B2 | Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2017-08-08 | — | — | US | disclosed |
| EP-2323985-B1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-2323985-B1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20150266900-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2015-09-24 | — | — | US | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2349262-B1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2184981-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051237-A1 | 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010017260-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020642-A1 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2005058298-A2 | FK228 ANALOGS AND THEIR USE AS HDAC-INHIBITORS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266900-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | CA9, CA7, CA2 | TAAR1 4175/4885KDM4E 1556/4885ATM 4374/4885 |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | TAAR1 86/4885KDM4E 1320/4885ATM 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.